Objective: To determine the prevalence of FSD in a hypertensive female population frequents medical specialized offices (internal medicine, cardiology and general medicine) in a spanish area and compare it to a group of women without hypertension of the same medical offices. Design and method: A cross-sectional analytical study was conducted on a sample of active women frequent users of a Cardiology, Internal Medicine and General Medicine Offices, in a spanish area. The validated questionnaire Female Sexual Function Index (FSFI) which assesses six aspects of female sexual function through an anonymous questionnaire administered to participants was used. Verbal informed consent to participating in the study was requested. Biographic and clinical data were collected, being established statistical significance at p < 0.005. Results: 216 women, of whom 108 had hypertension and 108 with no history or clinical data of hypertension were studied. The prevalence of FSD in hypertensive women was 65.8% compared with 44.5% among women without hypertension. A statistically significant association between FSD and hypertension (95% CI 1.08 to 5.1; p = 0.021 OR = 2.35) was found. The average age in hypertensive women was 60.5 years. It was not observed a significant difference in age between the the two groups. Significant differences in items of sexual desire, orgasm and lubrication were observed. The time evolution of hypertension was associated with statistically significantly with FSD (p = 0.008). In the hypertensive group had a statistically significant correlation between the number of active anti-hypertensive and DSF. Beta blockers were the drugs most associated with FSD in hypertensive women. Conclusions: FSD prevalence was higher in women with hypertension, posing a risk of FSD 2.35 times higher when compared to women without hypertension. The time evolution of the Hypertension, the number of drugs used and the use of beta-blockers was significantly correlated with the FSD. Physicians should be alert, we must suspect and must act an early stage about a problem that affects a large number of sexually active hypertensive women that can go unnoticed for many reasons.

Orgasm

Female sexual dysfunction

Cross-sectional study

10.1097/01.hjh.0000523138.59727.96

Cite

Citations (0)

[PP.07.12] HEMATOCRIT UREA AND GENDER (H.U.G.E.) FORMULA AND THE CKD PROGNOSIS CONSORTIUM EQUATION

Journal of Hypertension (2017)

Juan Manuel Urbano Gálvez Nicolás Roberto Robles Daniel Fernández‐Bergés Francisco Javier Félix-Redondo Luís Lozano

Objective: To compare, in the HERMEX survey sample, the results of the use of the CKD Prognosis Consortium equation to calculate the risk of end-stage renal disease with the results of the KDIGO Progression Risk Table and the HUGE formula. Design and method: From a sample of 2,813 subjects, 113 ones have an estimated glomerular filtration rate < 60 ml/min. Hematocrit, urea, creatinine and microalbuminuria were analyzed and then they were estimated the risk of progression to end-stage renal disease using the CKD Progression Consortium on line (http://www.kidneyfailurerisk.com), the risk of progression from the KDIGO Risk Table and the HUGE formula score. Results: Using the KDIGO Risk Table 83 (73.5%) of subjects were at medium risk, 23 (20.4%) ones at high risk and 7 (6.19%) patients at very high risk of progression of chronic kidney disease. Using the estimation from the CKD Consortium equation that calculate the risk of progression to end-stage renal failure 108 (95.6%) subjects were at low risk of progression, 2 (1.7%) ones had a medium risk and the three left (2.65%) had a high risk. Compared with KDIGO Risk Table, the sensitivity was 0.23 (95%CI 0.10–0.43) and the specificity was 1.0 (95%CI 0.94–1.00). The positive predictive value was 1.00 (95%CI 0.56–1.00) and the negative predictive value was 0.78 (95%CI 0.69–0.85). From the HUGE formula score only 33 (29.2%) patients had renal failure of them five have risk of progression to end-stage renal disease. The sensitivity was 1.00 (95%CI 0.46–1.00) and the specificity 0.74 (95%CI 0.65–0.82). The positive predictive value was 0.15 (95%CI 0.06–0.33) and the negative predictive value was 0.85 (95%CI 0.67–0.94). When H.U.GE formula results were compared with KDIGO Risk Table outcomes the sensitivity was 1.00 (95%CI 0.86–1.00) and the specificity was 0.96 (95%CI 0.89–0.99). Conclusions: There was not a good correlation between the KDIGO progression Risk Table and the equation to estimate end-stage renal disease risk. The KDIGO table must be used for nephrologist's referral. Contrariwise, the HUGE formula got a good correlation with the KDIGO table.

Microalbuminuria

10.1097/01.hjh.0000523369.07917.1b

Cite

Citations (0)

Abstract #599 Isolated Free T3 Thyrotoxicosis: Fact or Fiction?

Endocrine Practice (2019)

Dinkar Rupakula Juan Manuel Urbano Gálvez

10.1016/s1530-891x(20)46943-5

Cite

Citations (0)

[Postmenopausal metrorrhagia and endometrial pathology].

PubMed (1979)

Juan Manuel Urbano Gálvez J Prado L Norambuena

Metrorrhagia

Source

Cite

Citations (0)